Photo of Giulio Pasinetti

Giulio Pasinetti

  • PROFESSOR Neurology
  • PROFESSOR Psychiatry
  • PROFESSOR Neuroscience
  • PROFESSOR Geriatrics and Palliative Medicine
Print ProfilePrint Profile

Training Areas


  • M.D., University of Milan Medical School

  • Ph.D., University of Milan


    Dr. Giulio Maria Pasinetti is a Professor of Psychiatry, Professor of Neuroscience and Professor of Geriatrics and Adult Development, in the Department of Psychiatry at Mount Sinai School of Medicine, New York. Dr. Pasinetti graduated from Milan University School of Medicine in 1982, and he received his Ph.D. from the University of Milan in 1988. He joined the Mount Sinai School of Medicine's faculty in 1996 and has consistently maintained an outstanding record of excellence and exceptional productivity.

    Dr. Pasinetti is a recipient of several academic awards including the prestigious Zenith and Temple awards from the Alzheimer's Association. Most recently, Dr. Pasinetti was awarded ''The Faculty Council Award'' for academic excellence at Mount Sinai School of Medicine and "The Charles Dana Alliance for Brain Research Award"  from Dana Foundation, recognizing productivity and the worldwide leadership in his field of expertise, which further emphasizes his standing as an academic role model.

    Learn more about Dr. Pasinetti's research connecting diabetes and Alzheimer's disease in Inside Mount Sinai.

    Dr. Pasinetti was also recently awarded with an NIH funded research grant supporting a ''Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer's disease,'' of which he is the Principal Investigator and Director. The NIH funded Center is the first in the country exploring the potential beneficial role of natural grape -derived polyphenolic compounds implicated in mechanisms associated with the prevention of Alzheimer's disease (AD) neuropathology. Dr. Pasinetti also serves as the Director of the Basic and Biomedical Research and Training Program, GRECC James J. Peters Veterans Affairs Medical Center at the Bronx VA.


  • 2007 -
    Foundation Queen Sofia of Spain Research Center award on Alzheimer's Disease

  • 2005 -
    Faculty Council Award for Academic Excellence
    Mount Sinai School of Medicine

  • 2004 -
    Dana Alliance for Brain Initiatives Award

  • 2003 -
    Zenith Award from Alzheimer's Association

  • 2000 -
    Temple Foundation Discovery Award from Alzheimer's Association

  • 1994 -
    Nathan W. & Margaret T. Shock Aging Research Foundation Award of the Gerontology Society of America

  • 1991 -
    Turken Family fellowship from Alzheimer's Association
    Los Angeles Chapter

  • 1991 -
    Nathan Shock New Investigator Award of the Gerontology Society of America


Specific Clinical/Research Interest:
Neuronal Degeneration in Alzheimer's Disease and Model System

Postdoctoral Fellows:  Shrishailam Yemul, PhD, Merina Varghese, PhD

Research Personnel: Faculty: Lap Ho, PhD, Hanna Reding, PhD, Jun Wang, PhD, Bing Gong, PhD, Wei Zhao, PhD

Summary of Research Studies:
The primary research goals in Dr. Pasinetti's lab is to investigate the biological processes which occur when, during aging, subjects with normal cognitive functions convert into the very earliest stages of Alzheimer's disease (AD) and then to frank dementia. The long-term goal of Dr. Pasinetti's lab is to improve the diagnosis of patients who are in the very earliest stages of Alzheimer's disease (AD), and to identify early molecular neurobiological abnormalities so that effective pharmacological treatments to slow or halt disease progression can be developed. Toward this goal Dr. Pasinetti's lab initiated a series of studies to characterize gene activities in the brain of early AD cases and animal model system of AD neuropathology, using high throughput cDNA and microarray approaches. Recent studies in Dr. Pasinetti's lab found that the expression of genes involved in synaptic functions, cell cycle, and cytoskeleton/cell adhesion, may play an important role in the onset and possibly the clinical progression of Alzheimer's disease dementia. More recently, Dr. Pasinetti's lab using a combination of genomic-proteomic techniques is presently characterizing and purifying abnormal expressed gene products in the brain that may share similarities in respect with promotion of neurodegenerative disorders including amyotrophic lateral sclerosis and Parkinson's disease among others. Based on the outcome of these studies, Dr Pasinetti's lab is presently using newly developed transgenic mouse models of disease to test pre-clinically the potential therapeutic relevance of novel drug treatments. 


Wang J, Ferruzzi MG, Ho L, Blount J, Janle E, Gong B, Pan Y, Raftery D, Arrieta-Cruz I, Sharma V, Cooper B, Lobo J, Simon JE, Zhang C, Cheng A, Qian X, Ono K, Teplow D, Pavlides C, Dixon R, Pasinetti GM. Brain Targeting Proanthocyanidin Metabolites for Alzheimer’s Disease Treatment . Journal of Neuroscience In Press, 2012;.

Santa-Maria I, Varghese M, Księżak-Reding H, Dzhun A, Wang J, Pasinetti GM. Paired Helical Filaments from Alzheimer’s Disease Brain Induce Intracellular Accumulation of Tau in Aggresomes. Journal of Biological Chemistry In Press, 2012;.

Ho L, Varghese M, Wang J, Zhao W, Chen F, Knable LA, Ferruzzi M, Pasinetti GM. Dietary supplementation with decaffeinated green coffee improves diet-induced insulin resistance and brain energy metabolism in mice. Nutritional neuroscience 2012 Jan; 15(1).

Ho L, Zhao W, Dams-O'Connor K, Tang CY, Gordon W, Peskind ER, Haroutunian V, Pasinetti GM. Elevated plasma MCP-1 contents following traumatic brain injury as a potential “predisposition” factor associated with an increased risk for subsequent development of Alzheimer’s disease. Journal of Alzheimer's Disease In Press, 2012;.

Santa-Maria I, Diaz-Ruiz C, Ksiezak-Reding H, Chen A, Ho L, Wang J, Pasinetti GM. GSPE interferes with tau aggregation in vivo: implication for treating tauopathy. Neurobiology of aging 2011 Nov;.

Pasinetti GM, Wang J, Marambaud P, Ferruzzi M, Gregor P, Knable LA, Ho L. Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders. Experimental neurology 2011 Nov; 232(1).

Dixon RA, Pasinetti GM. Flavonoids and isoflavonoids: from plant biology to agriculture and neuroscience. Plant physiology 2010 Oct; 154(2).

Qin W, Ho L, Wang J, Peskind E, Pasinetti GM. S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PloS one 2009; 4(1).

Ho L, Yemul S, Wang J, Pasinetti GM. Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies. Journal of Alzheimer's disease : JAD 2009; 16(2).

Pasinetti GM, Eberstein JA. Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. Journal of neurochemistry 2008 Aug; 106(4).

Pasinetti GM. Anti-inflammator drugs fall short in Alzheimer's disease. Nature Medicine 2008, Commentary; 14(9).

Ono K, Condron MM, Ho L, Wang J, Zhao W, Pasinetti GM, Teplow DB. Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity. The Journal of biological chemistry 2008 Nov; 283(47).

Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. The Journal of clinical investigation 2007 Nov; 117(11).

Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiyagarajan M, MacGrogan D, Rodgers JT, Puigserver P, Sadoshima J, Deng H, Pedrini S, Gandy S, Sauve AA, Pasinetti GM. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. The Journal of biological chemistry 2006 Aug; 281(31).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Pasinetti did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.

Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.

Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


Annenberg Building Floor 20 Room 02 (Lab)
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-1952


Annenberg Building Floor Annenberg 20 Room 06
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-7938